Subsequent use of alternative FGFR2 inhibitors may lead to responses after progression, analogous to EGFR or ALK inhibitors in lung cancer.36 Additionally, divergent evolution mechanisms, such as PTEN aberrations, may also play a role in acquired resistance to FGFR2-targeted therapies.36 Thus, therapeutic combination strategies targeting FGFR2 and PTEN/PI3K/AKT may be speculatively intriguing to increase response duration, and/or overcome primary resistance in some FGFR2 fusion cases with co-occurring PTEN/PI3K alterations. Here, FGFR2 is linked to lung carcinoma.